» Articles » PMID: 33571835

Designing and Constructing a Phage Display Synthesized Single Domain Antibodies Library Based on Camel VHHs Frame for Screening and Identifying Humanized TNF-α-specific Nanobody

Overview
Date 2021 Feb 11
PMID 33571835
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor necrosis factor (TNF-α) is an important clinically tested cytokine that could induce autoimmune diseases and inflammation. Therefore, the anti-TNF-α therapy strategy was developed and used therapeutically in various diseases, especially in the cytokine storm associated chimeric antigen receptor (CAR) T-cell therapy and antiviral therapy. Compare with other anti-TNF-α inhibitors, anti-TNF-α Nb (nanobody) has many unique advantages. Herein, we reported a novel humanized scaffold for library construction, which could be soluble and expressed in Escherichia coli (E.coli), and the efficiency capacity could reach as high as 2.01 × 10. Meanwhile, an anti-TNF-α Nb was selected for further study after 4 rounds of screening, NT-3, as the optimal Nb could effectively inhibit TNF-mediated cytotoxicity. The IC50 of NT-3 was determined as 0.804 μM, and its apoptosis inhibition rate was 62.47 % in L929 cells. Furthermore, the molecular docking results showed that complementarity-determining regions (CDRs) of NT-3 could connect to TNF for blocking function through strong hydrogen bonds and salt bridges. In general, our study not only provided a good Nb screening platform in vitro without animal immunization, but also generated a series of novel humanized anti-TNF-α Nb candidates with potential applications.

Citing Articles

Construction of Immune Single Domain Antibodies Library for Development of Specific Nanobodies Using Phage Display Strategy.

El-Kalamawy H, Awwad M, Diab T, Okasha H, Abdel-Kareim A, Marawan M Recent Pat Biotechnol. 2025; 19(1):69-83.

PMID: 39840412 DOI: 10.2174/0118722083275669231227063413.


Single-chain antibody gene therapy strategy based on high-throughput screening triggers sustained antiviral activity in the body.

Zhao L, Wei X, Xu K, Zhao Z, Chen G, Wang H J Virol. 2024; 99(1):e0149724.

PMID: 39714166 PMC: 11784017. DOI: 10.1128/jvi.01497-24.


A new strategy to generate nanobodies for the coumaphos based on the synthesized nanobody libraries.

Fang R, Li Y, Liu F, Liang Y, Wang Y, Zhong G Food Chem. 2024; 455:139684.

PMID: 38833869 PMC: 11239888. DOI: 10.1016/j.foodchem.2024.139684.


Emerging Landscape of Nanobodies and Their Neutralizing Applications against SARS-CoV-2 Virus.

Feng X, Wang H ACS Pharmacol Transl Sci. 2023; 6(7):925-942.

PMID: 37470012 PMC: 10275483. DOI: 10.1021/acsptsci.3c00042.


Design of nanobody-based bispecific constructs by affinity maturation and umbrella sampling simulations.

Bai Z, Wang J, Li J, Yuan H, Wang P, Zhang M Comput Struct Biotechnol J. 2023; 21:601-613.

PMID: 36659922 PMC: 9822835. DOI: 10.1016/j.csbj.2022.12.021.